13F-HR filed by RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P. filed this 13F-HR for the quarter ended 2017-12-31, filed 2018-02-14, with 27 holding rows worth $1,195,149,000.
- Accession
- 0001144204-18-008963
- Filer
- CIK 1346824
- Filed
- 2018-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2017
A holdings report, 27 entries on the cover page, a total value of $1,195,149,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,195,149,000 with VALUE read as thousands by filing date, 13F file number 028-12884. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| WAVE LIFE SCIENCES LTD SHS | Y95308105 | Stock | 7,512,049 | $263,673,000 | thousands by filing date | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 5,580,690 | $223,562,000 | thousands by filing date | |
| AVEXIS INC | 05366U100 | COM | 1,171,278 | $129,625,000 | thousands by filing date | |
| SAGE THERAPEUTICS INC | 78667J108 | COM | 455,173 | $74,972,000 | thousands by filing date | |
| Inflarx Nv | N44821101 | COM | 2,876,080 | $60,254,000 | thousands by filing date | |
| BIOHAVEN PHARMACEUTICAL HOLDIN | G11196105 | COM | 1,997,278 | $53,887,000 | thousands by filing date | |
| ZOGENIX INC. | 98978L204 | Common Stock | 1,145,268 | $45,868,000 | thousands by filing date | |
| DICERNA PHARMACEUTICALS INC | 253031108 | COM | 4,965,513 | $44,839,000 | thousands by filing date | |
| KALA BIO INC COM | 483119103 | Stock | 2,113,236 | $39,074,000 | thousands by filing date | |
| MYOVANT SCIENCES LTD | G637AM102 | COMMON STOCK-FO | 2,830,455 | $35,777,000 | thousands by filing date | |
| SCPHARMACEUTICALS INC | 810648105 | COM | 2,857,143 | $34,543,000 | thousands by filing date | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 6,984,692 | $34,295,000 | thousands by filing date | |
| KADMON HLDGS INC | 48283N106 | COM | 6,269,342 | $22,695,000 | thousands by filing date | |
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 900,000 | $19,530,000 | thousands by filing date | |
| SPERO THERAPEUTICS INC | 84833T103 | COM | 1,225,647 | $14,401,000 | thousands by filing date | |
| ENDOCYTE INC | 29269A102 | COM | 3,364,648 | $14,401,000 | thousands by filing date | |
| AVEO PHARMACEUTICALS INC | 053588109 | COM | 5,062,759 | $14,125,000 | thousands by filing date | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 1,441,070 | $14,050,000 | thousands by filing date | |
| RA PHARMACEUTICALS INC | 74933V108 | COM | 1,351,808 | $11,490,000 | thousands by filing date | |
| SUNESIS PHARMACEUTICALS INC | 867328700 | COM | 3,096,840 | $11,427,000 | thousands by filing date | |
| CLEMENTIA PHARMACEUTICALS IN | 185575107 | COM | 585,403 | $11,111,000 | thousands by filing date | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 700,000 | $7,364,000 | thousands by filing date | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 75,816 | $4,787,000 | thousands by filing date | |
| G1 THERAPEUTICS INC | 3621LQ109 | COM | 159,780 | $3,170,000 | thousands by filing date | |
| PROTEON THERAPEUTICS INC | 74371L109 | COM | 1,337,462 | $2,541,000 | thousands by filing date | |
| CHIASMA INC | 16706W102 | COM | 1,176,806 | $2,001,000 | thousands by filing date | |
| ACHILLION PHARMACEUTICALS IN | 00448Q201 | COM | 585,890 | $1,687,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001144204-18-008963 | this filing | 2018-02-14 | acceptance time not in the bulk data set |